Evidence map›Paper›PMID 36708736›Full record

ReviewThe Lancet. Haematology2023

Expecting more: the case for incorporating fertility services into comprehensive sickle cell disease care.

Lydia H Pecker, Eugene Oteng-Ntim, Alecia Nero, Sophie Lanzkron, Mindy S Christianson, Teonna Woolford, Lillian R Meacham, Adrienne D Mishkin

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet. Haematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
18.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Insights Into the Expectations of Infertile Men Regarding Multidisciplinary Reproductive Health Services.Health expectations : an international journal of public participation in health care and health policy · 2025
    Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Lydia H PeckerDivision of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: lpecker1@jh.edu.
Eugene Oteng-NtimWomen's Health Academic Centre, King's College London, London, UK; Women's Services, Guy's and St Thomas' NHS Foundation Trust, London, UK; London School of Hygiene and Tropical Medicine, London, UK.
Alecia NeroDivision of Hematology-Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
Sophie LanzkronDivision of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Mindy S ChristiansonDepartment of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Division of Reproductive Endocrinology & Infertility, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Teonna WoolfordSickle Cell Reproductive Health Education Directive, Washington, DC, USA.
Lillian R MeachamAflac Cancer and Blood Disorders Center Children's Healthcare of Atlanta; Division of Hematology & Oncology, Department of Pediatrics Emory University, Atlanta, GA, USA.
Adrienne D MishkinBlood and Marrow Transplantation and Cell Therapy Program, Division of Hematology & Oncology and Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA.
Johns Hopkins University · USColumbia University Irving Medical Center · USEmory University · USKing's College London · GBThe University of Texas Southwestern Medical Center · US

Funding

Clinical and genetic risk factors associated with adverse long-term health outcomes after curative therapies in individuals with sickle cell diseaseU01HL156620 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DEBAUN, MICHAEL R., FITZHUGH, COURTNEY D · 2021 to 2025
$4.1M
OVARIAN RESERVE IN POST-MENARCHAL FEMALES WITH SICKLE CELL ANEMIAK23HL146841 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI PECKER, LYDIA · 2020 to 2024
$1.2M
NHLBI NIH HHS K23 HL146841NHLBI NIH HHS U01 HL156620
6 · The paper itself

Abstract

Assisted reproductive technologies (ART) are not yet systematically available to people with sickle cell disease or their parents. Fertility care for these groups requires addressing sickle cell disease-associated infertility risks, fertility preservation options, pregnancy possibilities and outcomes, and, when needed, infertility treatment. People with a chance of having a child with sickle cell disease can use in-vitro fertilisation with preimplantation genetic testing to conceive a child unaffected by sickle cell disease. Also, parents of children with sickle cell disease can use this technology to identify embryos to become potential future matched sibling donors for stem cell transplant. In the USA, disparities in fertility care for the sickle cell disease community are especially stark. Universal screening of newborn babies' identifies sickle cell disease and sickle cell trait, guidelines direct preconception genetic carrier screening, and standard-of-care fertility preserving options exist. However, potentially transformative treatments and cures for patients with sickle cell disease are not used due to iatrogenic infertility concerns. In diversely resourced care settings, obstacles to providing fertility care to people affected by sickle cell disease persist. In this Viewpoint, we contend that fertility care should be incorporated into the comprehensive care model for sickle cell disease, supporting alignment of treatment goals with reproductive life plans and delivering on the promise of individualised high-quality care for people with sickle cell disease and their families. We consider the obligation to provide fertility care in light of medical evidence, with acknowledgment of formidable obstacles to optimising care, and powerful historical and ethical considerations.

Indexed as

Anemia, Sickle CellFertility PreservationInfertilityChildFemaleFertilityGenetic TestingHumansInfantInfant, NewbornPregnancy

Identifiers

PMID36708736
PMCPMC10318482
OpenAlexW4318022913

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.